All In Biotech

Drug Trial Radar · NCT05881382

Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction

Phase 3, Randomized, Double-blind, Placebo-controlled, Safety and Efficacy Study of Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction

Last checked: Nov 20, 2026Latest source record: Jun 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 4,100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

4,100

Planned (sponsor's estimate)

Start

Sep 2023

Primary completion

Sep 2025

Study completion Sep 2025

Sponsor

Lead sponsor
Recardio, Inc.Industry
Sponsor type
Industry
First posted
May 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this phase 3, randomized, double-blind, placebo-controlled clinical trial is to explore the safety and efficacy of dutogliptin administered subcutaneously (SC) in co-administration with filgrastim in adult patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The primary objective is to evaluate the efficacy of dutogliptin compared with placebo in STEMI patients within 180 days of randomization measured by the time of first occurrence of a composite endpoint of cardiovascular (CV) death and worsening heart failure (HF) within 180 days. Participants will receive dutogliptin twice daily subcutaneously (SC) for 14 days and filgrastim (SC) daily for 5 days or placebo.

Conditions

  • ST Elevation Myocardial Infarction

Interventions

  • Dutogliptin + FilgrastimDrug

    dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.

  • PlaceboDrug

    Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time of first occurence of the following composite endpoint of cardiovascular (CV) death and worsening of heart failure (HF)Time frame: within 180 days of randomization

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.